Top

Journal of Gastrointestinal Surgery

Published in:

01-04-2011 | Original Article

The Potential of Osteopontin as a Therapeutic Target for Human Colorectal Cancer

Authors: Wang Likui, Wang Hong, Zhang Shuwen, You Yuangang, Wen Yan

Published in: Journal of Gastrointestinal Surgery | Issue 4/2011

Abstract

Objective

Osteopontin (OPN), a phosphorylated glycoprotein, is involved in tumor progression and metastasis. Previously, we have reported that high OPN mRNA expression level possessed clinicopathological or prognostic significance in human colorectal cancer (CRC). The aim of this study is to investigate whether OPN can serve as a novel molecular target for CRC therapy.

Material and Methods

Western Blot assay was performed to detect the expression of OPN protein in 18 CRC and corresponding nontumor colon tissue samples. RNA interference (RNAi) was employed to knockdown endogenous OPN expression in CRC cell line (LoVo). MTT, colony formation, and tumorigenicity assays were performed to analyze the effect of OPN downregulation on the in vitro and in vivo proliferation of CRC cells. Wound healing and Matrigel invasion assays were performed to analyze the effect of OPN downregulation on migration and invasion of CRC cells. A clonogenic cell survival assay after radiation was performed to analyze the effect of OPN downregulation on the radiosensitivity of CRC cells.

Results

The relative level of OPN protein expression in CRC tissues was significantly higher than that in corresponding nontumor colon tissues (P < 0.05). We found that RNAi-mediated OPN downregulation could inhibit not only in vitro proliferation but also in vivo tumorigenicity of CRC cells. In addition, OPN downregulation could suppress in vitro invasion capacity and enhance in vitro radiosensitivity of CRC cells, which might be associated with decreased levels of MMP-2 and -9 expression.

Conclusion

RNAi-targeting OPN could inhibit proliferation, invasion and enhance radiosensitivity of human CRC cells. Therefore, OPN could serve as a novel molecular target for gene therapy of CRC.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–249.PubMedCrossRef

Asmis TR, Saltz L. Systemic therapy for colon cancer. Gastroenterol Clin North Am 2008;37:287–295.PubMedCrossRef

Bulfone-Paus S, Paus R. Osteopontin as a new player in mast cell biology. Eur J Immunol 2008;38:338–341.PubMedCrossRef

Hu Z, Xiao T, Lin DM, Guo SP, Zhang ZQ, Di XB, Cheng SJ, Gao YN. Zhonghua Zhong Liu Za Zhi 2007;29:591–595.PubMed

Patani N, Jouhra F, Jiang W, Mokbel K. Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer Res 2008;28:4105–4110.PubMed

Wu IC, Wu MT, Chou SH, Yang SF, Goan YG, Lee JM, Chou YP, Bair MJ, Wang TE, Chen A, Chang WH, Kuo FC, Wu DC. Osteopontin expression in squamous cell cancer of the esophagus. World J Surg 2008;32:1989–1995.PubMedCrossRef

Cho H, Kang ES, Kim YT, Kim JH. Diagnostic and prognostic impact of osteopontin expression in endometrial cancer. Cancer Invest 2009;27:313–323.PubMedCrossRef

Higashiyama M, Ito T, Tanaka E, Shimada Y. Prognostic significance of osteopontin expression in human gastric carcinoma. Ann Surg Oncol 2007;14:3419–3427.PubMedCrossRef

Cappia S, Righi L, Mirabelli D, Ceppi P, Bacillo E, Ardissone F, Molinaro L, Scagliotti GV, Papotti M. Prognostic role of osteopontin expression in malignant pleural mesothelioma. Am J Clin Pathol 2008;130:58–64.PubMedCrossRef

10.

Likui W, Hong W, Shuwen Z. Clinical significance of the upregulated osteopontin mRNA expression in human colorectal cancer. J Gastrointest Surg 2010;14:74–81.PubMedCrossRef

11.

Hua D, Liu MY, Cheng ZD, Qin XJ, Zhang HM, Chen Y, Qin GJ, Liang G, Li JN, Han XF, Liu DX. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Mol Immunol 2009;46:2876–2884.PubMedCrossRef

12.

Zhang S, Yang JH, Guo CK, Cai PC. Gene silencing of TKTL1 by RNAi inhibits cell proliferation in human hepatoma cells. Cancer Lett 2007;253:108–114.PubMedCrossRef

13.

Wu X, Fan J, Wang X, Zhou J, Qiu S, Yu Y, Liu Y, Tang Z. Downregulation of CCR1 inhibits human hepatocellular carcinoma cell invasion. Biochem Biophys Res Commun 2007;355:866–871.PubMedCrossRef

14.

Li W, Jian W, Xiaoping X, Yingfeng L, Tao X, Xiaoyan X. Enhanced radiation-mediated cell killing of human cervical cancer cells by small interference RNA silencing of ataxia telangiectasia-mutated protein. Int J Gynecol Cancer 2006;16:1620–1630.PubMedCrossRef

15.

Liu H, Chen A, Guo F, Yuan L A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells. Cancer Lett 2010;295:27–37.PubMedCrossRef

16.

Waas ET, Wobbes T, Lomme RM, DeGroot J, Ruers T, Hendriks T. Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis. Br J Surg 2003;90:1556–1564.PubMedCrossRef

17.

Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004;90:1877–1881.PubMedCrossRef

18.

Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mänsson H. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev 2007;16:1087–1097.PubMedCrossRef

19.

Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002;94:513–521.PubMed

20.

Yeatman TJ, Chambers AF. Osteopontin and colon cancer progression. Clin Exp Metastasis 2003;20:85–90.PubMedCrossRef

21.

Wild N, Andres H, Rollinger W, Krause F, Dilba P, Tacke M, Karl J. A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res (2010);16(24):6111–6121.PubMedCrossRef

22.

Martinez C, Churchman M, Freeman T, Ilyas M. Osteopontin provides early proliferative drive and may be dependent upon aberrant c-myc signalling in murine intestinal tumours. Exp Mol Pathol 2010;88:272–277.PubMedCrossRef

23.

Matsuura M, Suzuki T, Saito T. Osteopontin is a new target molecule for ovarian clear cell carcinoma therapy. Cancer Sci 2010;101:1828–1833.PubMedCrossRef

24.

Matsuura M, Suzuki T, Suzuki M, Tanaka R, Ito E, Saito T. Statin-mediated reduction of osteopontin expression induces apoptosis and cell growth arrest in ovarian clear cell carcinoma. Oncol Rep 2011;25:41–47.PubMed

25.

Gong M, Lu Z, Fang G, Bi J, Xue X. A small interfering RNA targeting osteopontin as gastric cancer therapeutics. Cancer Lett 2008;272:148–159.PubMedCrossRef

26.

Mi Z, Guo H, Russell MB, Liu Y, Sullenger BA, Kuo PC. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther 2009;17:153–161.PubMedCrossRef

27.

Hahnel A, Wichmann H, Kappler M, Kotzsch M, Vordermark D, Taubert H, Bache M. Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. Radiat Oncol 2010;5:82.PubMedCrossRef

28.

Wai PY, Mi Z, Guo H, Sarraf-Yazdi S, Gao C, Wei J, Marroquin CE, Clary B, Kuo PC. Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis 2005;26:741–751.PubMedCrossRef

29.

Zhang A, Liu Y, Shen Y, Xu Y, Li X. Osteopontin silencing by small interfering RNA induces apoptosis and suppresses invasion in human renal carcinoma Caki-1 cells. Med Oncol 2010;27:1179–1184.PubMedCrossRef

30.

Lamour V, Le Mercier M, Lefranc F, Hagedorn M, Javerzat S, Bikfalvi A, Kiss R, Castronovo V, Bellahcène A. Selective osteopontin knockdown exerts anti-tumoral activity in a human glioblastoma model. Int J Cancer 2010;126:1797–1805.PubMed

Title: The Potential of Osteopontin as a Therapeutic Target for Human Colorectal Cancer
Authors: Wang Likui
Wang Hong
Zhang Shuwen
You Yuangang
Wen Yan
Publication date: 01-04-2011
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue 4/2011
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-011-1445-6

At a glance: The STEP trials

Springer Medicine

The Potential of Osteopontin as a Therapeutic Target for Human Colorectal Cancer

Abstract

Objective

Material and Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Material and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2011

Intestinal Cancer Risk in Crohn’s Disease: A Meta-Analysis

Anatomic Variations of Intrahepatic Bile Ducts in a European Series and Meta-analysis of the Literature

Ischemic Preconditioning Attenuates Lactate Release by the Liver During Hepatectomies Under Vascular Control: A Case–Control Study

Elective Resection of Colon Cancer by High-Volume Surgeons Is Associated with Decreased Morbidity and Mortality

Prognostic Value of Cirrhosis for Intrahepatic Cholangiocarcinoma After Surgical Treatment

Inflammatory Myofibroblastic Tumor of the Small Bowel Mesentery: An Unusual Cause of Abdominal Pain and Uveitis